-3.04%
-11.51%
-16.32%
-32.42%
-24.41%
-38.65%
68.37%
AI Spotlight on SLV
Company Description
Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally.It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics.The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing.
It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services.In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry.Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations.
Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.
Market Data
| Last Price | 44.6 |
| Change Percentage | -3.04% |
| Open | 45.8 |
| Previous Close | 46 |
| Market Cap ( Millions) | 818 |
| Volume | 3462 |
| Year High | 73 |
| Year Low | 44.6 |
| M A 50 | 49.68 |
| M A 200 | 60.34 |
Financial Ratios
| FCF Yield | 1.35% |
| Dividend Yield | 0.00% |
| ROE | 16.81% |
| Debt / Equity | 71.01% |
| Net Debt / EBIDTA | 427.92% |
| Price To Book | 2.62 |
| Price Earnings Ratio | 15.37 |
| Price To FCF | 73.84 |
| Price To sales | 2.47 |
| EV / EBITDA | 20.94 |
News
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Services Executed in Poland
Expected Growth : 10.27 %
What the company do ?
Selvita S.A. provides a range of services in Poland, including contract research, process chemistry, and custom synthesis, catering to the pharmaceutical and biotechnology industries.
Why we expect these perspectives ?
Selvita S.A.'s 10.27% growth in Services Executed in Poland is driven by increasing demand for contract research and development services, expansion of existing client relationships, and investments in digital transformation and process optimization. Additionally, Poland's favorable business environment, skilled workforce, and cost competitiveness contribute to the growth.
Segment n°2 -> Services Executed in Croatia
Expected Growth : 10.27 %
What the company do ?
Selvita S.A. provides a range of services in Croatia, including consulting, research, and development, primarily focused on life sciences and healthcare industries.
Why we expect these perspectives ?
Selvita S.A.'s services executed in Croatia grew 10.27% driven by increasing demand for R&D outsourcing, expansion of pharmaceutical and biotech companies in the region, and Croatia's favorable business environment. Additionally, Selvita's expertise in integrated drug discovery and development services, as well as its strategic partnerships, contributed to the growth.
Segment n°3 -> Elimination of Intersegment Revenue
Expected Growth : 9.27 %
What the company do ?
Elimination of Intersegment Revenue refers to the removal of revenue generated from transactions between Selvita S.A.'s different business segments, ensuring accurate financial reporting.
Why we expect these perspectives ?
Selvita S.A.'s 9.27% growth is driven by increasing demand for its innovative cancer therapies, strategic partnerships, and expansion into new markets. The company's strong R&D pipeline, cost optimization efforts, and effective sales strategy also contribute to its growth. Additionally, the elimination of intersegment revenue highlights the company's focus on high-margin businesses, further boosting its growth prospects.
Selvita S.A. Products
| Product Range | What is it ? |
|---|---|
| Integrated Drug Discovery | Selvita's Integrated Drug Discovery platform offers a comprehensive range of services, from target validation to lead optimization, to help clients accelerate their drug discovery programs. |
| Contract Research Services | Selvita provides contract research services, including in vitro and in vivo pharmacology, biochemistry, and analytical chemistry, to support clients' research and development programs. |
| Custom Synthesis | Selvita offers custom synthesis services, providing clients with high-quality, complex organic compounds, including small molecules, peptides, and nucleotides. |
| Computational Chemistry | Selvita's computational chemistry services utilize advanced modeling and simulation techniques to support clients' drug discovery and development programs. |
| Medicinal Chemistry | Selvita's medicinal chemistry services focus on the design, synthesis, and optimization of small molecules and peptides to support clients' drug discovery programs. |
Selvita S.A.'s Porter Forces
Threat Of Substitutes
Selvita S.A. operates in a niche market with high barriers to entry, reducing the threat of substitutes.
Bargaining Power Of Customers
Selvita S.A. has a diverse customer base, reducing the bargaining power of individual customers.
Bargaining Power Of Suppliers
Selvita S.A. relies on a few key suppliers, giving them some bargaining power, but the company's size and reputation mitigate this threat.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant capital requirements and regulatory hurdles, reducing the threat of new entrants.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established players and a high level of rivalry among them.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 32.82% |
| Debt Cost | 4.23% |
| Equity Weight | 67.18% |
| Equity Cost | 4.23% |
| WACC | 4.23% |
| Leverage | 48.85% |
Selvita S.A. : Quality Control
Selvita S.A. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CNTG | Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It … |
| CBAV.MC | Clínica Baviera, S.A., a medical company, operates a network of ophthalmology clinics. The company is involved in the diagnosis, treatment, and monitoring of various types of visual disorders. Its clinics … |
| VOX.WA | Voxel S.A. operates a network of diagnostic imaging laboratories. Its diagnostic imaging services include magnetic resonance imaging scans, computed tomography scans, positron emission tomography, and single photon emission computed tomography. … |
| VIMIAN.ST | Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription … |
| LBIRD.PA | Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two divisions, Photonics and Medical. The Photonics division offers solid-state lasers, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Clínica Baviera
A-Score
1-Year Total Return ->
🥈
Voxel
A-Score
1-Year Total Return ->
🥉
Selvita
A-Score
1-Year Total Return ->
4
Centogene
A-Score
1-Year Total Return ->
5
Vimian Group
A-Score
1-Year Total Return ->
6
